[go: up one dir, main page]

AU2235992A - Transgenic immunodeficient non-human animals - Google Patents

Transgenic immunodeficient non-human animals

Info

Publication number
AU2235992A
AU2235992A AU22359/92A AU2235992A AU2235992A AU 2235992 A AU2235992 A AU 2235992A AU 22359/92 A AU22359/92 A AU 22359/92A AU 2235992 A AU2235992 A AU 2235992A AU 2235992 A AU2235992 A AU 2235992A
Authority
AU
Australia
Prior art keywords
human animals
immunodeficient non
transgenic immunodeficient
transgenic
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22359/92A
Inventor
Manley T. F Huang
Cornelis P Terhorst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genpharm International Inc
Original Assignee
Genpharm International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genpharm International Inc filed Critical Genpharm International Inc
Publication of AU2235992A publication Critical patent/AU2235992A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU22359/92A 1991-06-14 1992-06-15 Transgenic immunodeficient non-human animals Abandoned AU2235992A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71665691A 1991-06-14 1991-06-14
US716656 1991-06-14
US84131792A 1992-02-25 1992-02-25
US841317 1997-04-30

Publications (1)

Publication Number Publication Date
AU2235992A true AU2235992A (en) 1993-01-12

Family

ID=27109578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22359/92A Abandoned AU2235992A (en) 1991-06-14 1992-06-15 Transgenic immunodeficient non-human animals

Country Status (2)

Country Link
AU (1) AU2235992A (en)
WO (1) WO1992022645A1 (en)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU6760794A (en) 1993-05-26 1994-12-20 Ontario Cancer Institute, The Transgenic mammals lacking expression of particular cd45 isoforms
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5532158A (en) * 1994-10-21 1996-07-02 Ontario Cancer Institute Interleukin-2 receptor deficient mammals
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ATE354655T1 (en) 1999-08-24 2007-03-15 Medarex Inc HUMAN ANTIBODIES TO CTLA-4 AND THEIR USES
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
DK1461442T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
EP2110434A1 (en) 2002-02-25 2009-10-21 Genentech, Inc. Type-1 cytokine receptor GLM-R
AU2003234736B2 (en) 2002-04-12 2008-09-25 E. R. Squibb & Sons, L.L.C. Methods of treatment using CTLA-4 antibodies
NZ554740A (en) 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US8067544B2 (en) 2003-03-19 2011-11-29 Curagen Corporation Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
BRPI0411803A (en) 2003-06-27 2006-05-23 Abgenix Inc antibodies directed to epidermal growth factor receptor deletion mutants and their uses
AU2003282780A1 (en) 2003-08-08 2005-03-07 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
EP1729804A2 (en) 2004-03-19 2006-12-13 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
PL1737891T3 (en) 2004-04-13 2013-08-30 Hoffmann La Roche Anti-p-selectin antibodies
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
US20060130157A1 (en) 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
AU2005319404B2 (en) 2004-12-20 2011-10-20 Amgen Fremont Inc. Binding proteins specific for human Matriptase
CN105085678B (en) 2004-12-21 2019-05-07 阿斯利康公司 Angiopoietin-2 antibody and its application
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
JP5225069B2 (en) 2005-03-23 2013-07-03 ゲンマブ エー／エス Antibodies against CD38 for the treatment of multiple myeloma
CN101325971A (en) 2005-12-07 2008-12-17 米德列斯公司 CTLA-4 antibody dose escalation regimens
ES2385054T3 (en) 2005-12-13 2012-07-17 Medimmune Limited Specific binding proteins for insulin-like growth factors and uses thereof
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
ES2709672T3 (en) 2006-01-12 2019-04-17 Alexion Pharma Inc Antibodies for OX-2 / CD200 and uses thereof
JP2009533028A (en) 2006-04-07 2009-09-17 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Antibody compositions and methods for the treatment of neoplastic diseases
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
CN103524619B (en) 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 Antibody and application thereof for α V β 6
PT2081595T (en) 2006-09-26 2019-07-16 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP2068928A2 (en) 2006-09-28 2009-06-17 Merck Serono SA Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
ES2456961T3 (en) 2007-02-21 2014-04-24 University Of Massachusetts Human antibodies against hepatitis C virus (HCV), uses thereof
JP5721951B2 (en) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and uses thereof
MX2009010282A (en) 2007-03-29 2009-10-12 Genmab As Bispecific antibodies and methods for production thereof.
EP2164873B2 (en) 2007-05-31 2018-09-12 Genmab A/S Stable igg4 antibodies
EP2615175B1 (en) 2007-05-31 2018-08-08 Genmab A/S Monovalent human antibodies
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2615113A3 (en) 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
PL2207809T3 (en) 2007-09-26 2014-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
CN101888856B (en) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 Antibody that binds to human dendritic and epithelial cells 205 (DEC-205)
CN101939336B (en) 2007-11-12 2014-05-14 U3制药有限公司 AXL antibodies
EP2245052B1 (en) 2008-01-25 2017-05-24 Aarhus Universitet Selective exosite inhibition of papp-a activity against igfbp-4
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
ES2548377T3 (en) 2008-10-27 2015-10-16 Revivicor, Inc. Immunosuppressed ungulates
CA3035432A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
RU2605318C2 (en) 2009-05-05 2016-12-20 Новиммун С.А. Anti-il-17f antibodies and methods for use thereof
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
IN2012DN04412A (en) 2009-11-09 2015-08-07 Alexion Pharmaceuticals Inc
EP3168232B1 (en) 2009-11-13 2021-09-29 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CN105999263B (en) 2009-11-13 2021-06-29 第一三共欧洲有限公司 Materials and methods for treating or preventing human epidermal growth factor receptor-3 (HER-3) related diseases
CA2778714C (en) 2009-11-24 2018-02-27 Medimmune Limited Targeted binding agents against b7-h1
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
CA3254586A1 (en) 2010-03-10 2025-11-29 Genmab A/S Monoclonal anti bodi es against c-met
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
ES2989108T3 (en) 2010-04-20 2024-11-25 Genmab As Proteins containing heterodimeric antibody FC and methods for producing the same
PT2563813E (en) 2010-04-30 2015-11-26 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
SI2580243T1 (en) 2010-06-09 2020-02-28 Genmab A/S Antibodies against human cd38
CA2802782C (en) 2010-06-15 2018-03-13 Genmab A/S Human antibody drug conjugates against tissue factor
EA201291328A1 (en) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт ANTIBODIES TO C3d FRAGMENT OF COMPONENT 3
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Ways to treat or prevent cholesterol disorders
JP6400470B2 (en) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド Multispecific Fab fusion proteins and methods of use
US10323081B2 (en) 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
US9221906B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of inhibiting solid tumor growth by administering GPR49 antibodies
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
EA201490974A1 (en) 2011-11-16 2014-09-30 Эмджен Инк. METHODS OF TREATMENT OF DISORDERS ASSOCIATED WITH DELIVERY MUTANT VIII EPIDERMAL GROWTH FACTOR
EP3578569A1 (en) 2012-02-06 2019-12-11 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
EP2859114B1 (en) 2012-06-11 2019-05-15 Amgen, Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
BR112015000167B1 (en) 2012-07-06 2021-11-23 Genmab B.V. DIMERIC PROTEIN, PROTEIN, COMPOSITION, KIT OF PARTS AND THEIR USES, AS WELL AS A METHOD TO INCREASE THE OLIGOMERIZATION IN SOLUTION OF A DIMERIC PROTEIN COMPRISING A FIRST AND SECOND POLYPEPTIDE, EACH COMPRISING AT LEAST ONE CH2 AND CH3 REGIONS HUMAN AND VARIANT DIMER PROTEIN
EA201500741A1 (en) 2013-01-10 2016-01-29 Генмаб Б.В. HUMAN FG IGG1 OPTIONS AND THEIR APPLICATION
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody combinations for CDH19 and CD3
PE20151408A1 (en) 2013-02-06 2015-10-15 Inhibrx Llc CD47 ANTIBODIES THAT DO NOT EXHAUST PLATELETS OR RED BALLOONS AND METHODS OF USING THEM
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
MX2016012873A (en) 2014-04-04 2017-03-07 Bionomics Inc Humanized antibodies that bind lgr5.
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
PT3169706T (en) 2014-07-11 2020-03-13 Genmab As ANTIBODIES THAT CONNECT TO AXL
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
TW201609812A (en) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 Optimized cross-species specific bispecific single chain antibody construct
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
SG11201703667SA (en) 2014-11-05 2017-06-29 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
CA2982682A1 (en) 2015-04-17 2016-10-20 Amgen Research (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
EP3319993B1 (en) 2015-07-10 2020-01-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
EA039859B1 (en) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
FI3334761T3 (en) 2015-08-13 2023-08-14 Univ New York Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
JP6959011B2 (en) 2016-02-03 2021-11-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ T cell engagement antibody construct with bispecificity to BCMA and CD3
MA43959A (en) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh CONSTRUCTIONS OF ANTIBODIES INVOLVING BISPECIFIC PSMA AND CD3 T-CELLS
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EP3429693B1 (en) 2016-03-15 2023-08-23 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Giving a bispecific formulation that binds to CD33 and CD3 for use in a modality for the treatment of myeloid leukemia
JP7029415B2 (en) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット Antibodies specific to hyperphosphorylated tau and how to use them
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
CU20210030A7 (en) 2016-10-13 2021-11-04 Massachusetts Inst Technology ANTIBODIES THAT BIND THE ZIKA VIRUS ENVELOPE PROTEIN
JP7217229B2 (en) 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット Agents, uses and methods for the treatment of synucleinopathies
CN110072888B (en) 2016-12-16 2023-07-18 H.隆德贝克有限公司 Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN118047864A (en) 2016-12-23 2024-05-17 百时美施贵宝公司 Design of Therapeutic Immunoglobulin G4 for Improved Bioanalytical and Bioprocessing Properties
MA47205A (en) 2017-01-04 2019-11-13 H Lundbeck As SPECIFIC ANTIBODIES OF HYPERPHOSPHORYLATED TAU PROTEIN TO TREAT EYE DISEASES
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
IL270239B2 (en) 2017-05-05 2025-01-01 Amgen Inc Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EA202091422A1 (en) 2017-12-11 2020-08-28 Эмджен Инк. METHOD FOR CONTINUOUS PRODUCTION OF PRODUCTS BASED ON BISPECIFIC ANTIBODIES
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
SG11202010993VA (en) 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
MX2020011176A (en) 2018-05-07 2020-11-12 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate.
MA53325A (en) 2018-07-30 2021-06-09 Amgen Inc PROLONGED ADMINISTRATION OF CD33 AND CD3-BINDING BISPECIFIC ANTIBODY CONSTRUCTION
TWI830761B (en) 2018-08-03 2024-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cldn18.2 and cd3
CA3109732A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
CN112867735B (en) 2018-09-07 2025-05-09 埃泰美德(香港)有限公司 Bispecific antigen binding proteins and uses thereof
CN112789058A (en) 2018-10-11 2021-05-11 安进公司 Downstream processing of bispecific antibody constructs
TWI844571B (en) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
CA3137494A1 (en) 2019-06-13 2020-12-17 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
WO2021021676A1 (en) 2019-07-26 2021-02-04 Amgen Inc. Anti-il13 antigen binding proteins
EP4028416A1 (en) 2019-09-10 2022-07-20 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
BR112022008557A2 (en) 2019-11-04 2022-08-09 Seagen Inc ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF HIV INFECTION
TW202132343A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202131954A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
UY38995A (en) 2019-12-20 2021-06-30 Amgen Inc MESOTHELIN TARGETING CD40 AGONIST MULTI-SPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
KR20220143005A (en) 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 Anti-interleukin-23 P19 antibodies and methods of use thereof
KR20220119467A (en) 2019-12-27 2022-08-29 아피메트 게엠베하 Methods of making the bispecific FCYRIII X CD30 antibody construct
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
CA3175275A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
MX2022014902A (en) 2020-05-29 2023-01-04 Amgen Inc Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3.
KR20230028492A (en) 2020-06-29 2023-02-28 젠맵 에이/에스 Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CA3193584A1 (en) 2020-09-04 2022-03-10 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Trispecific binders
AU2021374839A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
EP4240407A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
KR20230104229A (en) 2020-11-06 2023-07-07 암젠 인크 Polypeptide constructs that bind CD3
JP2023549581A (en) 2020-11-17 2023-11-27 シージェン インコーポレイテッド Method of treating cancer with a combination of tucatinib and anti-PD-1/anti-PD-L1 antibodies
EP4314078A1 (en) 2021-04-02 2024-02-07 Amgen Inc. Mageb2 binding constructs
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
AU2022377628A1 (en) 2021-10-29 2024-04-11 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
EP4426439A1 (en) 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
MX2024005397A (en) 2021-11-03 2024-05-23 Affimed Gmbh Bispecific cd16a binders.
TW202408583A (en) 2022-05-06 2024-03-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
EP4554624A1 (en) 2022-07-15 2025-05-21 Pheon Therapeutics Ltd Antibody-drug conjugates
JP2025533434A (en) 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド Bispecific molecular stabilization composition
JP2025541340A (en) 2022-12-16 2025-12-18 フィアン セラピューティクス エルティーディー Antibodies to CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) and uses thereof
AU2024302269A1 (en) 2023-06-14 2025-11-13 Amgen Inc. T cell engager masking molecules
TW202542182A (en) 2024-01-06 2025-11-01 美商生成生物醫學公司 Anti-il-13 antibodies and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026020031A2 (en) 2024-07-18 2026-01-22 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466815A4 (en) * 1989-04-05 1992-09-02 Novacell Corpporation Infectious targetted replication-defective virion
GB9100612D0 (en) * 1991-01-11 1991-02-27 Univ Edinburgh Method of altering the metabolic state of non-dividing cells,transgenic animals and therapeutic agents

Also Published As

Publication number Publication date
WO1992022645A1 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
AU2235992A (en) Transgenic immunodeficient non-human animals
AU2384488A (en) Virus-resistant transgenic animals
AU6819494A (en) Transgenic non-human animals capable of producing heterologous antibodies
EP0565189A3 (en) A construction for automatically milking animals
GB2267445B (en) Toys for cats
AU5135693A (en) Transgenic animal models for neurodegenerative disease
GB9307408D0 (en) Transgenic plants
EP0768027A3 (en) A Construction for automatically milking animals
GB2261148B (en) An improved aquarium
GB2252709B (en) Bedding for animals
EP0692187A3 (en) An implement for milking animals
GB9003966D0 (en) Improved dog kennel
AU6904794A (en) Transgenic animals having an engineered immune response
DE69305674D1 (en) Automatic bar feeder
IL99093A (en) Toy for farm animals
GB2263613B (en) Dog leash attachment
AU8735891A (en) B cell deficient transgenic non-human animals
GB9123314D0 (en) Transgenic animal production
AU2676692A (en) Transgenic plants
GB9503868D0 (en) Transgenic animals
GB9514535D0 (en) Transgenic animals
AU1711792A (en) Improved dehorning means
GB9201315D0 (en) A feeder for young animals
HU911470D0 (en) Lure for rodents
AU2003204055A1 (en) Transgenic non-human animals capable of producing heterologous antibodies